News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
455,522 Results
Type
Article (25312)
Company Profile (169)
Press Release (430041)
Section
Business (125342)
Career Advice (443)
Deals (20702)
Drug Delivery (40)
Drug Development (79352)
Employer Resources (43)
FDA (12696)
Job Trends (9419)
News (235649)
Policy (19052)
Tag
Academia (1743)
Alliances (34185)
Alzheimer's disease (1268)
Approvals (12643)
Artificial intelligence (152)
Bankruptcy (144)
Best Places to Work (8260)
Biotechnology (129)
Breast cancer (194)
Cancer (1455)
Cardiovascular disease (113)
Career advice (387)
CAR-T (106)
Cell therapy (288)
Clinical research (64854)
Collaboration (492)
Compensation (240)
COVID-19 (2063)
C-suite (115)
Data (1435)
Diabetes (151)
Diagnostics (5131)
Earnings (46983)
Events (72330)
Executive appointments (389)
FDA (13380)
Funding (433)
Gene therapy (190)
GLP-1 (468)
Government (2314)
Healthcare (13839)
Infectious disease (2143)
Inflammatory bowel disease (118)
IPO (10936)
Job creations (1515)
Job search strategy (349)
Layoffs (269)
Legal (2379)
Lung cancer (218)
Lymphoma (97)
Manufacturing (141)
Medical device (9171)
Medtech (9171)
Mergers & acquisitions (10052)
Metabolic disorders (377)
Neuroscience (1610)
NextGen: Class of 2025 (3937)
Non-profit (2428)
Northern California (1679)
Obesity (193)
Opinion (124)
Parkinson's disease (102)
Patents (91)
People (37276)
Phase I (20848)
Phase II (28914)
Phase III (20948)
Pipeline (571)
Postmarket research (2078)
Preclinical (7536)
Radiopharmaceuticals (238)
Rare diseases (254)
Real estate (2945)
Regulatory (15653)
Research institute (1861)
Southern California (1444)
Startups (2416)
United States (13660)
Vaccines (427)
Weight loss (110)
Date
Last 7 days (537)
Last 30 days (1599)
Last 365 days (29354)
2025 (1307)
2024 (29711)
2023 (33567)
2022 (41716)
2021 (43606)
2020 (40111)
2019 (31111)
2018 (23334)
2017 (24108)
2016 (22182)
2015 (25904)
2014 (18739)
2013 (14190)
2012 (14848)
2011 (15245)
2010 (14308)
Location
Africa (365)
Arizona (96)
Asia (27815)
Australia (5393)
California (3723)
Canada (1168)
China (321)
Colorado (162)
Connecticut (176)
Europe (63468)
Florida (470)
Georgia (120)
Illinois (262)
Indiana (180)
Japan (88)
Maryland (493)
Massachusetts (2796)
Michigan (108)
Minnesota (210)
New Jersey (958)
New York (1009)
North Carolina (659)
Northern California (1679)
Ohio (110)
Pennsylvania (823)
South America (487)
Southern California (1444)
Texas (542)
Utah (101)
Washington State (364)
455,522 Results for "aci clinical".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
LG Chem and Acies Bio Collaborate to Advance Sustainable Production of Chemicals
December 5, 2024
·
4 min read
Press Releases
Acies Bio and Protein Evolution Announce Strategic Partnership to Advance Biological Recycling Technology
November 21, 2024
·
3 min read
Press Releases
AC Immune Reports Interim Safety Data from Phase 1b/2 ABATE Trial of ACI-24.060 in Down syndrome
December 11, 2024
·
7 min read
Press Releases
AC Immune Reports Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease
November 14, 2024
·
5 min read
Press Releases
AC Immune Receives Second Milestone Payment Following Progress in Phase 2b ReTain Trial of ACI-35.030 in Preclinical Alzheimer’s Disease
September 18, 2024
·
7 min read
Press Releases
AC Immune’s ACI-35.030 (now “JNJ-2056”) Granted FDA Fast Track Designation for Alzheimer’s Disease
July 25, 2024
·
6 min read
AC Immune Clinical Data Published in Nature Communications Show Alpha-Synuclein PET Tracer ACI-12589 Has Potential as Neurodegenerative Disease Diagnostic
AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced the publication of a peer-reviewed paper in Nature Communications showing the ability of an alpha-synuclein (a-syn) positron emission tomography (PET) tracer to identify patients with multiple system atrophy (MSA).
October 27, 2023
·
5 min read
FDA
AC Immune Receives FDA Fast Track Designation for Anti-Amyloid-beta Active Immunotherapy, ACI-24.060, to Treat Alzheimer’s Disease
AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that it has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for its wholly-owned anti-amyloid beta (Abeta) active immunotherapy (vaccine)-candidate, ACI-24.060, for treatment of Alzheimer’s disease.
June 27, 2023
·
8 min read
Business
Anebulo Pharmaceuticals Reports Third Quarter Fiscal Year 2024 Financial Results and Recent Updates
Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid toxicities that include acute cannabinoid intoxication (ACI) and unintentional cannabis poisoning (the “Company” or “Anebulo”), today announced financial results for the three months ended March 31, 2024, and recent updates.
May 15, 2024
·
9 min read
Drug Development
AC Immune’s Alzheimer’s Disease Vaccine-candidate ACI-35.030 Selected for Further Development
AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that based on the Phase 1b/2a interim data, ACI-35.030, a potential first-in-class anti-phosphorylated-Tau (pTau) vaccine candidate, has been selected for further development.
November 30, 2022
·
6 min read
1 of 45,553
Next
